Study,Aug/20:Sex differences in benzo misuse in adults w/substance use disorders

The full title of this American study is "Sex differences in benzodiazepine misuse among adults with substance use disorders ".

https://pubmed.ncbi.nlm.nih.gov/32861991/

Abstract

Women are more likely than men to be diagnosed with anxiety disorders and to be prescribed benzodiazepines. People with substance use disorders are at a heightened risk for the misuse of benzodiazepines, yet little is known about sex differences in the prevalence, correlates or patterns of benzodiazepine misuse in this population. The aim of this study was to characterize sex differences in benzodiazepine misuse in a sample of adults receiving substance use disorder treatment (N = 352). Almost half of the sample had been prescribed a benzodiazepine and more than 40% had misused a benzodiazepine. Women were more likely to have a lifetime prescription than men, but were not more likely to report misuse or regular misuse. Consistent with data for other substances, women were more likely to report misusing benzodiazepines to cope and reported greater anxiety sensitivity. The vast majority (97%) of participants reported co-use of benzodiazepines with other substances and 65% of women reporting misusing benzodiazepines via a non-oral route of administration (e.g., intranasal). Although benzodiazepine misuse prevalence was not substantively different between men and women, several sex differences in clinical characteristics and patterns of use were identified. Further research on the nature of sex differences in benzodiazepine misuse is needed to inform targeted treatment for both men and women with substance use disorders.

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Drs. McHugh, Griffin and Bogunovic and Ms. Geyer and Chase report no potential conflicts of interest or other interests relevant to this manuscript. Dr. Weiss has been a consultant to Indivior, Alkermes, Braeburn Pharmaceuticals, GW Pharmaceuticals, US World Meds, Janssen Pharmaceuticals and Daiichi Sankyo.